全文获取类型
收费全文 | 135574篇 |
免费 | 9651篇 |
国内免费 | 555篇 |
专业分类
耳鼻咽喉 | 1498篇 |
儿科学 | 3997篇 |
妇产科学 | 2361篇 |
基础医学 | 18090篇 |
口腔科学 | 2614篇 |
临床医学 | 13525篇 |
内科学 | 28358篇 |
皮肤病学 | 1592篇 |
神经病学 | 12998篇 |
特种医学 | 4249篇 |
外国民族医学 | 2篇 |
外科学 | 19775篇 |
综合类 | 1971篇 |
现状与发展 | 1篇 |
一般理论 | 174篇 |
预防医学 | 12088篇 |
眼科学 | 3627篇 |
药学 | 9611篇 |
1篇 | |
中国医学 | 291篇 |
肿瘤学 | 8957篇 |
出版年
2023年 | 606篇 |
2022年 | 884篇 |
2021年 | 2534篇 |
2020年 | 1525篇 |
2019年 | 2596篇 |
2018年 | 3037篇 |
2017年 | 2232篇 |
2016年 | 2572篇 |
2015年 | 2968篇 |
2014年 | 4239篇 |
2013年 | 6002篇 |
2012年 | 9047篇 |
2011年 | 9678篇 |
2010年 | 5347篇 |
2009年 | 4959篇 |
2008年 | 8589篇 |
2007年 | 9098篇 |
2006年 | 8597篇 |
2005年 | 8679篇 |
2004年 | 8251篇 |
2003年 | 7644篇 |
2002年 | 7329篇 |
2001年 | 1575篇 |
2000年 | 1286篇 |
1999年 | 1579篇 |
1998年 | 1610篇 |
1997年 | 1383篇 |
1996年 | 1063篇 |
1995年 | 1060篇 |
1994年 | 897篇 |
1993年 | 899篇 |
1992年 | 909篇 |
1991年 | 853篇 |
1990年 | 801篇 |
1989年 | 734篇 |
1988年 | 715篇 |
1987年 | 657篇 |
1986年 | 649篇 |
1985年 | 685篇 |
1984年 | 721篇 |
1983年 | 685篇 |
1982年 | 817篇 |
1981年 | 717篇 |
1980年 | 662篇 |
1979年 | 528篇 |
1978年 | 488篇 |
1977年 | 483篇 |
1975年 | 402篇 |
1974年 | 422篇 |
1973年 | 405篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
4.
Breanne E. Kunstler Jill L. Cook Joanne L. Kemp Paul D. O’Halloran Caroline F. Finch 《Journal of Science and Medicine in Sport》2019,22(1):2-10
Objectives
To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.Design
Cross-sectional survey.Method
An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.Results
Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.Conclusions
Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy. 相似文献5.
6.
7.
8.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
9.